

## **Title Page**

# **Considering Age Variation when Coining Drugs as High vs Low Hepatic Extraction Ratio**

Farzaneh Salem, Khaled Abduljalil, Yoshi Kamiyama and Amin Rostami-Hodjegan

Simcyp Limited (a Certara Company), Sheffield, UK (FS, KA, ARH)

Astellas Pharma Inc, Drug Metabolism & Pharmacokinetics Management Analysis & Pharmacokinetics Labs, 21, Miyukigaoka, Tsukuba-shi, Ibaraki,305-8585, Japan (YK)

Centre for Applied Pharmaceutical Research, Manchester Pharmacy School, The University of Manchester, Stopford Building, Oxford Road, Manchester, M13 9PT, UK (YK, ARH)

## Running Title Page

**Running Title:** Consequences of Age Variation in Hepatic Extraction Ratios

**Corresponding Author:** Professor Amin Rostami-Hodjegan,

Centre for Applied Pharmaceutical Research, Manchester Pharmacy School, The University of Manchester, Stopford Building, Oxford Road, Manchester, M13 9PT, UK

Tel: +44 (0) 114 292 2330 Fax: +44 (0) 114 292 2333

E-mail: Amin.rostami@manchester.ac.uk

**Text pages:** 13 (Including References)

**Tables:** 1 (2 in Supplementary Material)

**Figures:** 3 (1 in Supplementary Material)

**References:** 17

**Abstract:** 254

**Introduction:** 333

**Discussion & conclusions:** 837

## Abbreviations

AAG, alpha-acid glycoprotein; B:P, Blood to plasma ratio;  $CL_{int,H}$ , Hepatic intrinsic clearance of unbound drug;  $CL_{H,B}$ , Hepatic metabolic clearance;  $E_H$ , Hepatic extraction ratio;  $f_u$ , Fraction of drug in plasma unbound;  $f_{uB}$ , Unbound drug in blood; MPPGL, Microsomal protein per gram of liver; PopPK, Population pharmacokinetics;  $Q_H$ , Hepatic blood flow.

## Abstract

Hepatic extraction ratio ( $E_H$ ) is commonly considered as ‘an inherent attribute’ of drug. It determines the main physiological and biological elements of the system (patient attributes) which are most significant in inter-individual variability of clearance.  $E_H$  consists of three age-dependent parameters: fraction of unbound drug in blood ( $f_{uB}$ ), hepatic intrinsic clearance of unbound drug ( $CL_{U_{int,H}}$ ) and hepatic blood flow ( $Q_H$ ). When age-effects on these elements are not proportional a given drug may shift from so called “high extraction” status to “low extraction”. To demonstrate the impact of age-related changes on  $f_{uB}$ ,  $CL_{U_{int,H}}$  and  $Q_H$ ,  $E_H$  of midazolam and two hypothetical drugs with 10-fold higher and 10-fold lower  $CL_{U_{int,H}}$  than midazolam were investigated in paediatrics based on known ontogeny functions.  $E_H$  was simulated using Simcyp V14. This was then complemented by a comprehensive literature survey to identify commonly applied covariates in paediatric population pharmacokinetic (PopPK) studies. Midazolam  $E_H$  decreased from 0.6 in adults to 0.02 at birth, making its clearance much more susceptible to changes in  $CL_{U_{int,H}}$  and  $f_{uB}$  than adults and reducing impact of  $Q_H$  on clearance. The drug with 10-fold higher  $CL_{U_{int,H}}$  was categorised as high extraction from 4 days old onwards, whilst the drug with 10-fold lower  $CL_{U_{int,H}}$  remained low extraction from birth to adulthood. Approximately 50% of collected PopPK studies ( $n=120$ ) did not consider interaction between age and other covariates. Interaction between covariates and age should be considered as part of studies involving young paediatric patients.  $E_H$  cannot be considered as an inherent drug property without considering the effect of age.

## Introduction

Hepatic metabolic clearance ( $CL_{H,B}$ ) of intravenously administered drugs is determined by hepatic blood flow ( $Q_H$ ) and their hepatic extraction ratio ( $E_H$ ) according to the Equation 1:

$$CL_{H,B} = E_H \times Q_H \quad \text{Equation 1}$$

$E_H$  is calculated from fraction of drug unbound in blood ( $f_{u,B}$ ), hepatic intrinsic clearance of unbound drug ( $CL_{u,int,H}$ ) and  $Q_H$  according to Equation 2:

$$E_H = \frac{f_{u,B} \times CL_{u,int,H}}{Q_H + (f_{u,B} \times CL_{u,int,H})} \quad \text{Equation 2}$$

Extraction ratio of the drug is generally classified as high ( $>0.7$ ), intermediate ( $0.3-0.7$ ) or low ( $<0.3$ ) according to the fraction of drug removed during one pass through the liver. Commonly  $E_H$  of a drug is considered as an inherent attribute of the drug and presented with a fixed value. However, this classification does not consider that the parameters in Equation 2 are age-dependent and changes in these parameters will affect  $E_H$ . For example, a rise in  $f_{u,B}$ , for low  $E_H$  drugs increases hepatic metabolic clearance, whereas for high extraction drugs this does not affect metabolic clearance. Unless the age-related physiological changes in  $f_{u,B}$ ,  $CL_{u,int,H}$  and  $Q_H$  occur in parallel, it is expected that  $E_H$  of drugs varies with age. Therefore, a high extraction drug in adults will not necessarily remain a high extraction drug in neonates.

Age-varying  $E_H$  can potentially be used as a covariate in clearance models when analysing population pharmacokinetic (PopPK) studies. However, since applying extraction ratio directly in the model might not be straightforward this concept is considered in PopPK models through the interaction between covariate terms in the model. For example, age and body weight are commonly used as covariates in PopPK clearance models where body weight is also affected by age. The interaction between these two covariates should be considered in the model.

The primary aim of this study is to investigate relative differences in  $E_H$  with age using *in vivo* midazolam data and two hypothetical high and low extraction drugs through modelling and

simulation techniques. We also use the concept of the age varying  $E_H$  to examine whether the interaction between covariate terms in modelling clearance have been considered in the PopPK studies.

## Materials and Methods

### Literature Data collection

Data on midazolam systemic clearance in paediatrics from birth to 17 years were collected from the literature. Literature search strategy and methodology for deconvolution of clearance to arrive at  $CL_{H,B}$  from midazolam systemic clearance (using blood to plasma ratio (B:P)) and  $Q_H$  based on cardiac output were explained previously (Salem et al., 2014).

### Simulations

A drug with 10-fold higher and 10-fold lower  $CL_{U_{int,H}}$  than midazolam was designed by multiplying and dividing the deconvoluted midazolam  $CL_{U_{int,H}}$  by 10 as proposed by (Salem et al., 2014) to mimic a high and low extraction drug, respectively. Then, using the relevant  $CL_{U_{int,H}}$ ,  $Q_H$  and  $f_{uB}$  in Equation 2,  $E_H$  was calculated.

A number of simulations in Simcyp Paediatric v14 were carried out for midazolam, a drug with 10-fold higher and 10-fold lower  $CL_{U_{int,H}}$  than midazolam to show age related changes in the magnitude of  $E_H$ . One hundred subjects were simulated consisting of equal proportion of males and females and combination of age bands (1 day, 1 month, 2 years and 12 years as well as adult).  $E_H$  was calculated using Equation 3 from the output data. Mean values of  $E_H$  at each age band were plotted against age for each of the simulated drugs.

### Calculation of hepatic extraction ratio

Hepatic extraction ratio was calculated from  $CL_H$  and  $Q_H$  for midazolam and the other two hypothetical drugs assuming well-stirred model using Equation 3;

$$\text{Hepatic Extraction Ratio} = \frac{CL_{H,B}}{Q_H} \quad \text{Equation 3}$$

### Sensitivity analysis

Sensitivity analysis was carried out with a view to identify which component of the extraction ratio ( $CL_{U_{int,H}}$ ,  $Q_H$  and  $f_{uB}$ ) plays the most dominant role in variation of  $E_H$  from those of adult

values at any given age. The impact of age dependent  $Q_H$  was evaluated by fixing  $f_{u_B}$  and  $CL_{U_{int,H}}$  (L/h/g of liver) to the adult values for all age ranges. This involved assumptions on lack of any ontogeny for abundance of the enzymes (pmol per mg of microsomal protein) and no age related changes in the level of microsomal protein per gram of liver (MPPGL). The values of  $CL_{U_{int,H}}$  (L/h/g of liver) were used to calculate the paediatric  $CL_{U_{int,H}}$  values per whole liver by applying age-related liver weight.  $E_H$  was plotted against age and patterns were compared. In another set, only  $f_{u_B}$  values were fixed to adult values to demonstrate the sensitivity of  $E_H$  to age related changes in  $Q_H$  and  $CL_{U_{int,H}}$  (L/h) without impact of age-related changes in binding.  $E_H$  was calculated and plotted against age and compared with the original set of results (where all age-related parameters had been considered).

In order to separate the size related effects (i.e. liver mass and hepatic blood flow) from ontogeny-related factors on  $E_H$ , a graphical representation was devised to demonstrate the paediatric values of enzyme abundance relative to adults at given age (in this case CYP3A4) alongside relative values for liver volume, hepatic blood flow and MPPGL.

### **Population Pharmacokinetic studies (PopPK)**

A comprehensive literature survey using Pubmed was carried out to identify commonly used covariates in paediatric PopPK studies for drugs after intravenous administration. No year or journal or language restriction applied to the search process. Collated publications were carefully checked for modelling covariates and the form of the covariates-clearance relationship in the reported model. Studies that considered the interaction between covariates and clearance were identified. Interaction between covariate terms was also considered if the presence of a covariate modifies the impact of another covariate in a multiplicative or exponential way. Where there are different clearance models for different paediatric age ranges, interaction with age is also considered. Interaction between covariate terms was not considered if only one covariate was considered in the final clearance model or if the covariates are in linear additive relationship to the clearance. Corresponding authors were contacted where modelling section was not clear.

## Results

### Midazolam hepatic extraction ratio

Hepatic extraction ratio of midazolam, after deconvolution of clinical systemic clearance, increased with age. Figure 1 illustrates that midazolam is a low extraction drug until about the age of 10 months. However, in some individuals it remained low at the age of 9 years.

Figure 2 shows  $E_H$  increases with age for midazolam and two other hypothetical compounds. The degree of change in  $E_H$  with age depends on magnitude of  $CL_{U_{int,H}}$  against the given enzyme. As shown in the figure, 10-fold reduction in  $CL_{U_{int,H}}$  results in a drug with low hepatic extraction across the paediatric and adult age range whereas 10-fold increase in  $CL_{U_{int,H}}$  shifts the drug from so called intermediate to high extraction status.

### Sensitivity analysis

Figure 2 compares  $E_H$  when all age related components ( $CL_{U_{int,H}}$ ,  $Q_H$  and  $f_{u_B}$ ) considered (solid lines) with a scenario involving no age-related changes in  $f_{u_B}$  (dashed lines). As shown in Figure 2  $E_H$  is marginally lower in younger groups if age related  $f_{u_B}$  is not considered. However, this might be different for drugs with higher protein binding.

When  $CL_{U_{int,H}}$  (L/h/g of liver) and  $f_{u_B}$  are fixed to adult values, the changes in  $E_H$  will be driven by age-related changes in  $Q_H$  and liver weight (Supplemental Figure 1). In this scenario, there are no significant differences between  $E_H$  values across paediatric age groups for three drugs since the low activity of CYP3A4 in younger age is not considered.

The rate of change with age for liver volume, hepatic blood flow and MPPGL as a fraction of adult values are shown in Figure 3. This figure shows the changes in underlying parameters of  $E_H$ . The changes in blood flow and liver volume relative to adults occurs almost in parallel to each other. Therefore, the discrepancy in  $Q_H$  and liver size alone cannot account for the observed differences in  $E_H$  instead changes in intrinsic activity to the level of enzyme abundance and to a lesser extent MPPGL are determinants of age-varying  $E_H$ . **Error!**

**Reference source not found.** summarises the contributing parameters to  $E_H$  that are reported



in Figure 3. Needless to say, if relative values to adult for all these elements had a similar rate of change with age, no age-related differences would have been anticipated in  $E_H$ .

### **Analysis of covariates in population pharmacokinetic (PopPK) studies**

A total of 120 PopPK studies were retrieved in paediatric age range (birth to 18 years) for intravenously administered drugs. The interaction between covariate terms was not considered in 50% of the studies (n=60). Table S1 in supplements summarises the most commonly used covariates in the analysed PopPK studies (Supplemental Table 1). Table S2 in supplements shows all the analysed PopPK studies with interaction between covariates (Supplemental Table 2).

## Discussion and Conclusions

$E_H$  of the drugs in this study increases with age due to rapid physiological changes in parameters determining  $E_H$  after birth including the ontogeny of enzyme abundance and to a lesser extent MPPGL. Although not relevant to the cases represented in this study, ontogeny of plasma proteins can play a significant role in age-related changes of  $E_H$  for highly bound, low extraction drugs. As shown previously by several authors, concentration of plasma proteins increases with age whereas unbound fraction of drugs in plasma and therefore in blood decreases with age (Sethi et al., 2015, Johnson et al., 2006 and McNamara and Alcorn, 2002). The ontogeny of plasma protein binding and enzyme abundance on any given compound depends on the extent of binding to particular protein and the importance of that enzymatic pathway to the overall elimination of drug. As a consequence, a drug that is coined a high, low or intermediate hepatic extraction compound in adults is not necessarily going to carry the same extraction category in paediatrics. For the particular case studies in this report, where the binding was not a major factor, and CYP3A4 was the main metabolising enzyme, we demonstrated the switch from high extraction or intermediate extraction to low extraction in neonates and younger children. However, the results from this study should be generalised to other drugs metabolised by other pathways with caution.  $CL_{U_{int,H}}$  value is an interplay between the enzyme abundance and kinetic parameters ( $V_{max}$  and  $K_m$ ). The difference in enzyme abundance depending on the pathway and age can be masked or stressed by enzyme kinetic parameters and hence resulting in similar or different  $CL_{U_{int,H}}$  and  $E_H$  values from what has been shown in this study. Changes in  $E_H$  is not confined to age-varying parameters. Induction or inhibition of drug metabolising enzymes for a capacity limited drug and inhibition of drug metabolising enzyme for a flow limited drug can also change the extraction ratio of drugs. In addition changes to  $Q_H$  and  $f_{uB}$  due to hemodynamic changes occurring in clinical conditions and progression of disease may affect the extraction ratio of drugs. This consideration can be more important in preterm neonates due to prematurity of metabolic pathways, special populations such as elderly and pregnancy that can affect free fraction of the drug ( $f_u$ ), enzyme activity and/or  $Q_H$  which ultimately can alter  $E_H$ .

Since the determinants of CL (covariates) change with age, it is not right to assume no-interaction between age and covariates. In some of the analysed PopPK studies here, the interaction between covariate terms were not identified by their authors. The reason for lack of such interactions can be the wide age range in some of these studies with limited number of subjects at lower end of spectrum. In addition, several investigations only examined older subsets of children, where the ontogeny of enzymes responsible for metabolism are likely to be fully mature. These investigations are not likely to find that the addition of age into their clearance models provide a better fit. Another reason for lack of interaction origins from unbalanced blood sampling in the early life after birth compared with older children. Some pharmacokinetic studies retrospectively analysed the available samples of drug concentration in blood or plasma where the relevant covariates are not always available. Also some relevant covariates such as  $f_u$  may not have been measured in new-borns. Only one PopPK study on morphine concluded an independent clearance model is required for new-borns (Knibbe et al., 2009).

The results in this study suggest that  $CL_{u,int,H}$  is the most important parameter that affects  $E_H$  of drugs. Due to rapid physiological changes after birth and especially in neonatal period  $E_H$  of drugs can be significantly affected by changes in  $CL_{u,int,H}$ .

Hepatic extraction also contributes to determination of oral bioavailability of drugs. Currently, there are contradicting evidence as to bioavailability of drugs is different between paediatrics and adults (Harper et al., 1988; Stratchunsky et al., 1991; Pinkerton et al., 1993; Hassan et al., 1994; Fujiwara et al., 1996; Anderson et al., 2002; Crill et al., 2006; Zane and Thakker, 2014). While in clinical practice bioavailability of drugs is assumed to be similar between paediatrics and adults, the current study supports bioavailability also can be an age-dependant parameter and reduce with age since  $E_H$  changes with age. Assuming a higher hepatic extraction and therefore lower bioavailability in neonates, oral clearance can be overestimated in this population and unnecessarily higher doses given to neonates. However, the clinical significance of this under and overestimations is not clear and requires further investigation.

In conclusion, a high extraction drug in adults is not necessarily a high extraction drug in paediatrics. Unless the age-related changes in factors determining  $E_H$  occur at the same rate, extraction ratio will be different between paediatrics and adults. More attention should be given to interaction terms of covariate during analysis of such data as the impact of certain physiological covariates might change with age. Further clarification of underlying mechanisms for metabolism (and bioavailability) of drugs should heavily rely on modelling and simulation techniques.

## **Acknowledgments**

The authors are grateful to the reviewers of this manuscript for their considerable input and constructive comments which significantly expanded the scope of this article. We also thank Miss Eleanor Savill for assistance with preparation of the manuscript.

## **Authorship Contributions:**

Participated in research design: Salem, Abduljalil, Kamiyama, Rostami-Hodjegan

Performed data analysis: Salem, Abduljalil, Kamiyama

Wrote or contributed to the writing of the manuscript: Salem, Abduljalil

## References

- Anderson BJ, Van Lingen RA, Hansen TG, Lin YC and Holford NH (2002) Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. *Anesthesiology* **96**:1336-1345.
- Barter ZE, Chowdry JE, Harlow JR, Snawder JE, Lipscomb JC, Rostami-Hodjegan A (2008) Covariation of human microsomal protein per gram of liver with age: Absence of influence of operator and sample storage may justify interlaboratory data pooling. *Drug Metab Dispos* **36**:2405-2409.
- Crill CM, Christensen ML, Storm MC and Helms RA (2006) Relative bioavailability of carnitine supplementation in premature neonates. *J Parenter Enter Nutr* **30**:421-425.
- Fujiwara Y, Ohune T, Okusaki K, Niitani K, Sumiyoshi H, Takemoto Y, Yamaoka N and Yamakido M (1996) Bioavailability of 50- and 75-mg oral etoposide in lung cancer patients. *Cancer Chemother Pharmacol* **37**:327-331.
- Guyton AC (1991) *Cardiac Output, Venous Return, and Their Regulation*. In: Textbook of Medical Physiology, 8th ed. W.B.Saunders Company, Philadelphia.
- Harper P, Elwin CE and Cederblad G (1988) Pharmacokinetics of bolus intravenous and oral doses of l-carnitine in healthy-subjects. *Eur J Clin Pharmacol* **35**:69-75.
- Hassan M, Ljungman P, Bolme P, Ringden O, Syruckova Z, Bekassy A, Sary J, Wallin I and Kallberg N (1994) Busulfan bioavailability. *Blood* **84**:2144-2150.
- Johnson TN, Sabzghabae A, Rostami-Hodjegan A, Tucker GT (2003) Prediction of age related changes in midazolam clearance in children, in *Proceedings of the British Pharmacological Society Clinical Pharmacology Section 7-10 January 2003, Br J Clin Pharmacol* **55**:418-449
- Johnson TN, Tucker GT, Tanner MS and Rostami-Hodjegan A (2005) Changes in Liver Volume from Birth to Adulthood: A Meta-Analysis. *Liver Transpl* **12**:1481-1493.
- Johnson TN, Rostami-Hodjegan A and Tucker GT (2006) Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. *Clin Pharmacokinet* **45**:931-956.

- Knibbe CA, Krekels EH, Van Den Anker JN, Dejongh J, Santen GW, Van Dijk M, Simons SH, Van Lingen RA, Jacqz-Aigrain EM, Danhof M and Tibboel D (2009) Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. *Clin Pharmacokinet* **48**:371-385.
- McNamara PJ and Alcorn J (2002) Protein binding predictions in infants. *AAPS PharmSci* **4**:E4
- Pinkerton CR, Dick G and Aherne GW (1993) 24-Hour plasma etoposide profile after oral and intravenous administration in children. *Eur J Cancer* **29A**:1479-1481.
- Salem F, Johnson TN, Abduljalil K, Tucker GT and Rostami-Hodjegan A (2014) A re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data. *Clin Pharmacokinet* **53**:625-636.
- Sethi PK, White CA, Cummings BS, Hines RN, Muralidhara S, Bruckner JV (2015) Ontogeny of plasma proteins, albumin and binding of diazepam, cyclosporine and deltamethrin. *Pediatr Res* Epub ahead of print.
- Stratchunsky LS, Nazarov AD, Firsov AA and Petrachenkova NA (1991) Age dependence of erythromycin rectal bioavailability in children. *Eur J Drug Metab Pharmacokinet Spec* **No 3**:321-323.
- Zane NR and Thakker DR (2014) A Physiologically Based Pharmacokinetic Model for Voriconazole Disposition Predicts Intestinal First-pass Metabolism in Children. *Clin Pharmacokinet* **53**:1171-1182.

## Figure Legends

**Figure 1** Hepatic extraction for intravenous midazolam calculated from reports of clinical studies in the literature using ontogeny functions in paediatric subjects and healthy adult volunteers (n=523).

**Figure 2** Simulated hepatic extraction in Simcyp v14 shows changes with age for midazolam, a drug with 10-fold higher  $CL_{U_{int,H}}$  and a drug with 10-fold lower  $CL_{U_{int,H}}$ . A high or intermediate extraction drug in adults is not necessarily a high or intermediate extraction drug in paediatric subjects. Dashed lines are the same  $E_H$  values with age when  $f_{u_B}$  is remained unchanged ( $f_{u_B}=0.05$ ). Dotted lines show the limits for high ( $>0.7$ ) and low ( $0.3>$ ) extraction.

**Figure 3** Age-related variations in parameters defining  $E_H$  shown as relative values to corresponding adult level of each parameter. Part (A) indicates the changes in liver size (Johnson et al., 2005), hepatic blood flow (Guyton., 1991) and MPPGL (Barter et al., 2008) which applies to all drugs. Part (B) demonstrates the relative values of serum albumin (Johnson et al., 2003, Johnson et al., 2006 and Sethi et al., 2015), CYP3A4 abundance (of relevance to current study) (Salem et al., 2014) alongside age-variation in serum alpha-acid glycoprotein (AAG) (Johnson et al., 2003 and Johnson et al., 2006) and CYP1A2 abundance (Salem et al., 2014). The impact of the parameters shown in Part (B) will depend on the relative importance of the protein binding to each protein and the role of the specific enzyme to overall elimination.



## Tables

**Table 1.** Examples of age-related parameters defining  $E_H$  and prior knowledge on their age-dependency

Parameter	Definition	Age-dependency Model
$Q_H$	Hepatic blood flow as a function of cardiac index	Guyton, 1991
MPPGL	mg of microsomal protein per gram of liver	Barter et al., 2008
CYP3A4 and CYP1A”	pmol of enzyme abundance	Salem et al., 2014
Liver volume	ml of liver	Johnson et al., 2005
Albumin and AAG	Plasma proteins concentration (g/L)	Johnson et al., 2006 and Sethi et al., 2015

**Figure 1**




Figure 2






Figure 3



Downloaded from dmnd.aspejournals.org at ASPET Journals on April 18, 2024